Key facts
- This page summarizes Dr. Robert T. Foster's Form 4 filing for Hepion Pharmaceuticals, Inc. (HEPA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 19 Sep 2023, 09:01.
Dr. Robert T. Foster - 18 Sep 2023 Form 4 Insider Report for Hepion Pharmaceuticals, Inc. (HEPA)
- Reporting relationship
- CEO and Director, Director
- Issuer ticker
- HEPA
- Reported as of
- 18 Sep 2023
- Net transaction value
- +$8,960
- SEC form
- 4
- Accepted by SEC
- 19 Sep 2023, 09:01:30 UTC
- Prior SEC filing
- 18 Sep 2023
- Next SEC filing
- 22 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Foster
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Dr. Robert T. Foster filed Form 4 for Hepion Pharmaceuticals, Inc. (HEPA) on 19 Sep 2023.
Change
- Previous filing in this sequence was filed on 18 Sep 2023.
- Current net transaction value: +$8,960.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HEPA
transaction
Common Stock
Purchase
- Transaction value
- $8,960
- Shares
- +1,600
- Change %
- +3.3%
- Price
- $5.60
- Shares after
- 50,470
- Date
- 18 Sep 2023
- Ownership
- Direct
* marks a reported price that did not pass the local price check.